Irinotecan Sun

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Sun, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer and other advanced solid tumors in adult patients.

GNH USA supplies Irinotecan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and clinical use across multiple regions globally.

Irinotecan Sun is employed in oncology to treat cancers that are responsive to topoisomerase I inhibition. - Metastatic colorectal cancer: improves survival when used in combination chemotherapy regimens. - Advanced solid tumors: provides antitumor activity in various non‑colorectal malignancies. - Disease progression after fluoropyrimidine therapy: used as a second‑line option in combination protocols.

Irinotecan Sun may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea - Neutropenia (low white blood cells) - Fatigue

Serious or Rare Side Effects: - Febrile neutropenia - Severe colitis or intestinal perforation - Allergic or anaphylactic reactions

Before initiating therapy, clinicians should consider several safety measures. - Baseline blood counts: obtain a complete blood count prior to the first dose. - Liver function: monitor hepatic enzymes regularly during treatment. - Renal function: assess creatinine clearance before each cycle. - Concurrent myelosuppressive therapy: avoid or adjust dosing to reduce additive bone‑marrow toxicity. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Sun can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce irinotecan exposure and therapeutic effect. - UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 levels and raise the risk of severe toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency. - Other myelosuppressive agents: increase the likelihood of profound bone‑marrow suppression. - Fluoropyrimidines (e.g., 5‑FU): heightened gastrointestinal toxicity, especially diarrhea.